Blocking Pyk2 to improve immune therapy for aggressive brain cancer
Pyk2 inhibition mitigates immunosuppressive environment and enhances therapeutic response to immune checkpoint inhibitors in GBM
This study is looking at how blocking a protein called Pyk2 might help make glioblastoma, a tough brain cancer, more sensitive to treatments that use the immune system, so that patients can have better responses to their therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Universidad Central Del Caribe NIH-funded |
| Lab location | 1 site (Bayamon, United States) |
| Project ID | NIH-11059876 on NIH RePORTER |
What this research studies
This research investigates how inhibiting a protein called Pyk2 can change the environment around glioblastoma (GBM), a deadly brain cancer, to make it more responsive to immune therapies. The study will analyze human GBM samples and use mouse models to understand how Pyk2 contributes to the cancer's ability to evade the immune system. By targeting Pyk2, the researchers aim to enhance the effectiveness of existing treatments that utilize the body's immune response against tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with recurrent glioblastoma who have not responded to current immune checkpoint therapies.
Not a fit: Patients with non-brain cancers or those whose glioblastoma has not recurred may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with glioblastoma by making their tumors more susceptible to immune therapies.
How similar studies have performed: Previous research has shown promise in targeting similar pathways to enhance immune responses in various cancers, suggesting potential for success in this approach.
Where this research is happening
Bayamon, United States
- Universidad Central Del Caribe — Bayamon, United States (Active)
Researchers
- Principal investigator: Kucheryavykh, Lilia — Universidad Central Del Caribe
- Study coordinator: Kucheryavykh, Lilia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.